21st Austria weekly - Marinomed, Mayr-Melnhof (14/03/2023)

Marinomed: Marinomed Biotech AG, listed on the Vienna Stock Exchange, announced positive results from its clinical study on the decongestant effect of the Sorbitol-containing Carragelose nasal spray. The double-blind, two-way cross-over, randomized and placebo-controlled study was conducted at the Vienna Challenge Chamber. While Carragelose was shown to be an effective treatment of viral infections of the respiratory tract, Sorbitol exerts a decongestant effect. Therefore, the product is indicated for the supportive treatment of rhinitis of any kind with the symptom of a blocked nose. Using the product as a treatment against allergies may help to both relieve the allergy symptoms and to reduce the risk of a viral respiratory infection. The latter is particularly important because respiratory viral infections may cause a worsening of the underlying allergic disorder in these patients. The Carragelose and Sorbitol nasal spray was launched in 2018 and is currently marketed in 11 countries as a common cold product. Based on the current clinical results, Marinomed plans to expand both the applications and target markets for the decongestant nasal spray.
Marinomed Biotech: weekly performance: -5.13%

Mayr-Melnhof: Cartonboard group Mayr-Melnhof grew strongly in 2022. The Group’s consolidated sales reached EUR 4,682.1 million, which is 52.5 % or EUR 1,612.4 million above the previous year’s figure (2021: EUR 3,069.7 million). On the one hand, this rise resulted from the previous year's acquisitions in the MM Board & Paper division as well as the company purchases of MM Packaging in the reporting year and, on the other hand from passing on costs through higher prices. At EUR 510.3 million, an operating profit of EUR 240.7 million above the previous year (2021: EUR 269.6 million) was achieved. Peter Oswald, MM CEO, comments: “The MM Group grew significantly in terms of profit and sales, both organically and through acquisitions, in a macroeconomically and geopolitically challenging environment in the financial year 2022. Profit for the year thus increased by EUR 154.5 million to EUR 345.2 million (2021: EUR 190.7 million). In line with the good profit development and long-term dividend policy, a dividend increase to EUR 4.20 per share (2021: EUR 3.50) for the financial year 2022 will be proposed to the 29^th Annual Shareholders’ Meeting on April 26, 2023.
Mayr-Melnhof: weekly performance: -6.05%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (14/03/2023)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #1060: AT&S begrüsst Gerrit Steen mit Kursplus, Gunter Deuber likes Porr, OMV und Palfinger, Opening Bell Marianne Kögel

Bildnachweis

1. Mayr-Melnhof - Key Combined Pro Forma Financials Overview   >> Öffnen auf photaq.com

Aktien auf dem Radar:VIG, Kapsch TrafficCom, Austriacard Holdings AG, EuroTeleSites AG, Pierer Mobility, Flughafen Wien, ATX, ATX Prime, ATX TR, ATX NTR, Rosgix, Bawag, Andritz, AT&S, Mayr-Melnhof, voestalpine, Rosenbauer, EVN, Frequentis, BKS Bank Stamm, Oberbank AG Stamm, Amag, CPI Europe AG, Lenzing, Österreichische Post, RHI Magnesita.

Random Partner

---

BNP Paribas
BNP Paribas ist eine führende europäische Bank mit internationaler Reichweite. Sie ist mit mehr als 190.000 Mitarbeitern in 74 Ländern vertreten, davon über 146.000 in Europa. BNP Paribas ist in vielen Bereichen Marktführer oder besetzt Schlüsselpositionen am Markt und gehört weltweit zu den kapitalstärksten Banken.

>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner